Since Ii and CLIP are involved in both HLA-I and HLA-II antigen presentation, it will be attractive to design immunotherapeutic strategies that modulate their expression, thereby controlling antigen presentation with the purpose to target immune surveillance against leukemias and possibly prevent autoimmunity. The gene discussed is CD74; the disease is leukemia.